P123: Donor-cell Derived Hematological Neoplasm: Case Presentations of a Complex and Rare Event

Jeanine Ruggeri,Billie Carstens,Veronica McDaniel, Christine Henderson,Hala Nijmeh,Patricia Trevisan,Sudabeh Balakhani,Kimberly Harding, Aline Murakami-Walter, Alexandra Ohene-Mobley,Karen Swisshelm, Stephen Wicks, Laura Schultz-Rogers,Mary Haag

Genetics in Medicine Open（2024）

Cited 0|Views11

No score

Abstract

Allogenic stem cell transplants (allo-SCT) are a common treatment option for hematological neoplasms. Despite being a routine treatment modality, it can result in complications such as Graft Versus Host Disease (GVHD) or relapse of the disease of origin. A less well documented adverse outcome of allo-SCT is donor-cell derived hematological neoplasm (DCHN) which can cause considerable disruption in patient care. The following case presentations highlight the heterogeneity of DCHN and possible roadblocks in confirming this phenomenon in patients post allo-SCT.

Translated text

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined